Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)

v3.23.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Other $ 2,191 $ 3,080
Total accrued expenses and other current liabilities 12,393 14,764
Supply Agreement | Vaxcyte    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals 5,274 4,830
CMO    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals 2,404 3,900
Clinical Trials    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals $ 2,524 $ 2,954